August 22, 2014 1:57 PM ET

Pharmaceuticals

Company Overview of Labopharm Inc.

Company Overview

Labopharm Inc., a specialty pharmaceutical company, develops drugs by incorporating its proprietary controlled-release technologies worldwide. It offers once-daily formulation of the analgesic tramadol under the RYZOLT brand name for the treatment of patients with moderate to moderately severe pain; Oleptro, a novel once-daily formulation of trazodone for the treatment of major depressive disorder; and twice-daily formulation combining the analgesics tramadol and acetaminophen for the treatment of pain. The company’s novel and proprietary drug delivery technologies include Intellitab technology for the development of abuse-and misuse-deterrent formulations of drugs; polymeric nano-delivery s...

480 Armand-Frappier Boulevard

Laval, QC H7V 4B4

Canada

Founded in 1990

Phone:

450-686-1017

Fax:

450-686-9141

Key Executives for Labopharm Inc.

Chief Executive Officer
Age: 53
Chief Financial Officer
Senior Vice President of Research & Development
Managing Director of Labopharm Europe Limited
Chief Medical Officer
Compensation as of Fiscal Year 2014.

Labopharm Inc. Key Developments

Altus Formulation Signs Agreement With Zogenix for Development of Abuse Deterrent Formulations of Zohydro(TM) ER

Altus Formulation Inc. announced that it has entered into a Development and Option Agreement with Zogenix, Inc., to develop abuse deterrent formulations of Zohydro(TM) ER using Altus's proprietary, clinically validated Intellitab drug delivery platform. Altus and Zogenix have initiated development of Intellitab abuse deterrent formulations of Zohydro ER with the entry into the agreement. Zohydro(TM) ER (hydrocodone bitartrate) extended-release capsules, an opioid agonist, is the first approved extended-release oral formulation of hydrocodone without acetaminophen, for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Zogenix, Inc. Pursues Development of Abuse Deterrent Formulations of Zohydro(TM) ER with Altus Formulation Inc

Zogenix Inc. announced that it has entered into a Development and Option Agreement with Altus Formulation Inc. to develop abuse deterrent formulations of Zohydro(TM) ER (hydrocodone bitartrate) extended-release capsules, using Altus's proprietary Intellitab(TM) drug delivery platform. Concurrent with entry into this agreement, Altus and Zogenix have initiated development of alternative abuse deterrent formulations of Zohydro ER. Under the D&O Agreement, Altus has granted Zogenix an option (subject to the terms and conditions of the D&O Agreement) to enter into an exclusive license on mutually agreed terms to develop and commercialize abuse deterrent formulations of Zohydro ER in the United States. In connection with the transaction, Zogenix will pay Altus a technology access fee in the amount of $750,000. Zogenix will fund all development activities, and Altus may earn up to an additional $3.5 million in development and regulatory milestones through submission of a New Drug Application (NDA) under the D&O Agreement. Following exercise of the option, Altus will be eligible to receive additional undisclosed regulatory and sales milestone payments and a royalty based on net sales of the licensed product.

Similar Private Companies By Industry

Company Name Region
Pro Doc Ltée Americas
8816301 Canada Inc. Americas
Advanced Orthomolecular Research Inc. Americas
NRL Pharma Canada Inc. Americas
Alphora Research Inc. Americas

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Labopharm Inc., please visit www.labopharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.